Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8132510 | 0.85 | LMNA (0.53) | KDM4ETP53LMNAHIF1ASMN1; SMN2 | |
| SCHEMBL7953183 | 0.82 | ALDH1A1 (0.46) | KDM4ETP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL7948937 | 0.73 | EGFR (0.40) | LMNAUSP2TSHRRPS6KB1ALDH1A1 | |
| SCHEMBL7937354 | 0.72 | KDM4E (0.51) | KDM4ENPSR1TP53MAPTLMNA | |
| SCHEMBL9222308 | 0.70 | TSHR (0.51) | KDM4ENPSR1TP53MAPTLMNA | |
| SCHEMBL28090340 | 0.68 | LMNA (0.49) | KDM4ENPSR1TP53MAPTLMNA | |
| SCHEMBL27855323 | 0.68 | TAAR1 (0.53) | KDM4ELMNAHIF1ASMN1; SMN2TSHR | |
| SCHEMBL7973444 | 0.65 | RPS6KB1 (0.47) | KDM4ETP53LMNAHIF1ASMN1; SMN2 | |
| SCHEMBL30775396 | 0.65 | CSF1R (0.49) | KDM4ETP53LMNAHIF1ASMN1; SMN2 | |
| SCHEMBL9723536 | 0.65 | ADRA2A (0.37) | KDM4ENPSR1TP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2279742-A2 | Combinations for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | claimed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | COMBINATORX, INCORPORATED | 2008-01-31 | — | — | US | claimed |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | COMBINATORX, INC. | 2008-01-03 | — | — | US | claimed |
| WO-2007146012-A1 | TREATMENT OF PERIODONTAL DISEASE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007139753-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN, INTERLEUKIN-6, OR INTERFERON-GAMMA LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
| JP-2001517226-A | — | — | 2001-10-02 | — | — | JP | claimed |
| EP-0971925-A1 | PYRIMIDOPYRIMIDINE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-01-19 | — | — | EP | claimed |
| WO-1998043974-A1 | PYRIMIDOPYRIMIDINE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-10-08 | — | — | WO | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-0971925-A1 | PYRIMIDOPYRIMIDINE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998043974-A1 | PYRIMIDOPYRIMIDINE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | KDM4E 2040/4885NPSR1 434/4885TP53 1375/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | KDM4E 3208/4885NPSR1 2421/4885TP53 1536/4885 |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | TYMP, TTR, TPMT | KDM4E 3637/4885NPSR1 2755/4885TP53 1793/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | KDM4E 3832/4885NPSR1 1398/4885TP53 2277/4885 |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | IFNG, IL6, IL36G | KDM4E 4269/4885NPSR1 3282/4885TP53 1895/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | KDM4E 3208/4885NPSR1 2421/4885TP53 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.